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Abstract Radiofrequency thermal ablation (RFTA) is
considered the treatment of choice for osteoid osteomas, in
which it has long been safely used. Other benign conditions
(chondroblastoma, osteoblastoma, giant cell tumour, etc.)
can also be treated by this technique, which is less invasive
than traditional surgical procedures. RFTA ablation is also
an option for the palliation of localized, painful osteolytic
metastatic and myeloma lesions. The reduction in pain
improves the quality of life of patients with cancer, who
often have multiple morbidities and a limited life expec-
tancy. In some cases, these patients are treated with RFTA
because conventional therapies (surgery, radiotherapy,
chemotherapy, etc.) have been exhausted. In other cases, it
is combined with conventional therapies or other percuta-
neous treatments, e.g., cementoplasty, offering faster pain
relief and bone strengthening. A multidisciplinary
approach to the management of these patients is recom-
mended to select the optimal treatment, including
orthopaedic surgeons, neurosurgeons, medical and radia-
tion oncologists and interventional radiologists.
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Introduction
Cancer has traditionally been treated either systemically
with chemotherapy or locally with surgery or radiotherapy.
Recent advancements in minimally invasive therapies are
adding further tools for cancer management, e.g., che-
moablation, thermal ablation, percutaneous grafting,
acetabuloplasty and vertebroplasty [1, 2].
In thermal ablation, tumours are heated to temperatures
above 60C until the tumour cells are killed. It can be
produced by microwaves, radiofrequency (RF), high-
intensity ultrasound (US) or laser [3, 4]. Thermal ablation
also includes cryotherapy, in which tumour necrosis is
achieved by freezing to below -20C[ 5].
Image-guided RF thermal ablation (RFTA) is used in
interventional oncology to coagulate and destroy tumour
tissue by the direct application of RF-generated heat [6].
The term refers to coagulation induction from all electro-
magnetic energy sources with frequencies less than
30 MHz, with most currently available devices functioning
in the 375–500 kHz range [7]. It is the most commonly
used technology for thermal ablation in bone, liver, kidney,
lung, heart, breast, lymph nodes, nerve ganglia and soft
tissue.
This article addresses the use of RFTA in the treatment
of bone tumours and tumour-like lesions.
Image guidance
Image guidance is critical to the success of this therapy.
Computed tomography (CT) is preferred over other imag-
ing techniques (ultrasound [US], magnetic resonance
imaging [MR], and ﬂuoroscopy) to treat bone tumours,
because it provides faster imaging acquisition and a better
anatomic resolution of the bone tissue.
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1. Pre-procedure: assessment of the volume and conﬁg-
uration of the tumour for selection of the appropriate
size of active electrode tip and planning of a safe
approach to the lesion that avoids sensitive neurovas-
cular structures.
2. Intra-procedure: monitoring of the introductory nee-
dles during the procedure and ensuring the correct
localization of the non-insulated active tip of the
electrode.
3. Post-procedure: follow-up of patients, preferentially by
means of MRI after bone treatment in order to
minimize their radiation dose. It is also recommended
to assure the technical success of the procedure by
demonstrating that bone necrosis cover the treated
tumour [6, 8].
Instrumentation
The RF device comprises an electric generator connected
to a probe or electrode and grounding pads (Fig. 1). An
electrical circuit is formed in the patient by placing the
electrode tip in the bone lesion and the grounding pads on
the thighs. The electric current from the RF generator ﬂows
through the electrode into the patient and out through the
grounding pads back to the generator. It consists of an
alternating current of high-frequency radio waves that pass
from the non-insulated electrode tip to the tissue and
dissipate their energy as heat, leading to cell death and
coagulation necrosis. Heat is produced by resistive forces
that produce ionic and molecular agitation in the tissues
surrounding the electrode during attempts by the radio
waves to return to the ground pads [9].
RF energy is applied with a metal electrode (14–21 G)
covered with insulating material except at the tip, with an
active tip length of 0.7–3 cm. Many types of electrodes are
available: monopolar, with a single electrode; bipolar, with
two electrodes; cluster, with three or more closely spaced
electrodes of \1 cm; and umbrella or multitined expand-
able electrodes, with an array of multiple electrode tines
that expand from a larger, centrally positioned needle
cannula.
Some electrodes are internally cooled by saline or water
that ﬂows in an internal lumen not in direct contact with
patient tissues. Perfusion electrodes have small apertures at
the active tip that allow ﬂuids to be infused or injected into
the tissue before, during or after the ablation procedure [6,
8].
The type of electrode and size of active tip inﬂuence the
size and morphology of induced tumour necrosis. A rod
electrode is usually more appropriate in bone tumour
treatment, because it can be inserted through a drilled hole.
The distribution of heat around rod monopolar electrodes
can be expected to follow a cylindrical contour with
rounded edges. Most heat generation is produced in tissues
with lower resistance, and tissue resistivity is much higher
in cortical than marrow bone. Hence, cortical tissue is
Fig. 1 Instrumentation used in
the procedure. a
Radiofrequency generator. b
Grounding pads on the thigh of
a patient. c Electrode, biopsy
trephine and verterbroplasty
needle. d Electrode inserted
through vertebroplasty cannula
in the thigh of a patient
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when intact, protecting surrounding soft tissues and carti-
lage [9].
At our centre, we use a hammer, vertebroplasty needle
(100 cm, 13 or 10 G) and biopsy trephine (150 cm, 13 or
15 G) to reach the bone lesions and open up an entry
channel for the electrode (Fig. 1).
Procedure
The procedure can be performed under general anaesthesia
or conscious sedation. Nerve blockage can be used when
limbs are involved.
After imaging the whole bone lesion, the appropriate
approach route is selected in order to obtain a complete
treatment of the bone tumour after the fewest possible
ablation sessions. When the route must pass close to sen-
sitive anatomic structures (blood vessels, nerves), the
needle is carefully introduced in short steps.
An intramuscular needle is ﬁrst inserted at the selected
site to guide the entry of the thicker vertebroplasty needle.
CT monitoring allows any deviations from the route to be
corrected, and the needle is placed in the bone up to the
edge of the tumour. A biopsy trephine is then introduced to
obtain material for the pathology study, creating a channel
for the entry of the RF electrode. After the correct insertion
of the electrode and without displacing it, the guide can-
nula is withdrawn as far as possible to avoid its contact
with the active electrode tip, which could heat the cannula
and burn the pathway and skin.
Immediately afterwards (within 30–60 s), the power
output is increased to 90C and dry ablation is performed
for 6 min. In large lesions, the vertebroplasty needle is
moved to another selected site, repeating the procedure as
often as necessary.
A typical RF treatment has an output reading of less
than 10 W and an impedance of less than 150 X. Once the
treatment is completed, the RF electrode is removed and a
small dressing is applied to the skin [10].
Bone tumour treatment by RFTA
Image-guided RFTA reduces the pain and improves the
function and quality of life of patients with painful bone
tumours. It has been used to treat benign bone tumours and
tumour-like lesions as a single modality or as an adjunct to
surgical therapy. CT-guided radiofrequency or laser abla-
tion is the gold standard procedure for most osteoid
osteomas [11].
RF or laser thermal ablation also offers an alternative
method for palliation of localized and painful osteolytic
metastatic lesions [12]. The reduction in pain that can be
obtained improves the quality of life for patients with
cancer, who often have multiple morbidities and a limited
life expectancy. A multidisciplinary approach to the man-
agement of these patients is recommended in order to select
the optimal treatment, including orthopaedic surgeons,
neurosurgeons, medical and radiation oncologists and
interventional radiologists.
Osteoid osteoma
Osteoid osteoma, ﬁrst described in 1935 [13], is a benign
osteogenic tumour most frequently observed in the cortex
of long bones in children and young adults. It is relatively
common and accounts for around 10% of all benign bone
tumours [14].
There are three distinct management options: surgery,
percutaneous therapy and conservative medical treatment.
Although cases of spontaneous regression have been
reported [15], the prolonged presence of the tumour may
lead to complications, including growth disturbances,
scoliosis and osteoarthritis [16]. Medical management used
to be appropriate when the alternative was traditional sur-
gical resection. However, RFTA, with its high success
rates, low complication rates and short recovery period can
now be considered the treatment of choice for most osteoid
osteomas located in the appendicular skeleton and pelvis
(Fig. 2).
Fig. 2 a Osteoid osteoma
located in the anterior cortex of
the femoral neck in a child. b
Electrode in place and guide
cannula withdrawn
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when a presumptive diagnosis is made based on history,
clinical examination and CT. TC
99 Scintigraphy also plays
an important role in deﬁning an active lesion.
The technical and clinical success of RFTA in osteoid
osteomas was ﬁrst reported by Rosenthal [17] in 1992.
Subsequently, most reports on radiofrequency ablation of
osteoid osteoma have described clinical success in 73–
100% of patients, with few complications and a short
hospital stay [11, 18, 19]. Our experience is limited to 15
cases and clinical success was achieved in 14 (93%); pain
returned in one patient with tibial osteoid osteoma, who
subsequently underwent surgery.
Other bone tumour or tumour-like lesions
Other benign bone conditions are also suitable for RFTA
treatment, including giant cell tumour, chondroblastoma,
osteoblastoma, haemangioma, eosinophilic granuloma and
enchondroma.
Chondroblastomas are benign cartilaginous lesions that
are usually detected in patients under 20 years old. They
generally grow at the epiphysis or apophysis of the
immature skeleton, hampering surgical removal, and
RFTA has been reported as an alternative curative therapy
in these cases [20, 21] (Fig. 3). Unlike osteoid osteomas,
there is a tendency to progression.
Erickson et al. described the ﬁrst application of RFTA in
three cases of chondroblastomas, ﬁnding no evidence of
recurrence in follow-up periods ranging from 2 to 4 years
[21]. We are aware of three subsequent studies on the
successful treatment of chondroblastomas with RFTA. The
ﬁrst reported on four young patients and described an
association between lesion size and articular collapse,
which was observed in two of them [20]. The second
described the avoidance of articular collapse by the com-
bined use of RFTA and bone grafting [22]. The third
reported that a patient with chondroblastoma at the greater
tuberosity of the humerus was asymptomatic at 6 months
[23].Our experience is limited to two cases, in which RFTA
was combined with percutaneous cementation (Fig. 3). The
patients remain asymptomatic more than 2 years later.
Osteoblastoma is a rare, benign, bone-forming tumour
that is histologically related to the more common osteoid
Fig. 3 a CT scan of a
chondroblatoma of distal
femoral epiphysis. b Biopsy
trephine within tumour. c
Electrode within tumour. d
Radiography of lesion after
ablation and cementation
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30 years of age. Despite its benign nature, this tumour can
exhibit aggressive behaviour and become larger than an
osteoid osteoma (C2 cm) (Fig. 4). Recurrences are not
uncommon after classic treatment by surgical excision or
curettage [24]. RFTA is a less invasive alternative and
performed in the same way as for osteoid osteomas, using
electrodes with a longer active tip or a greater number of
ablation sessions or multi-tip array probes [25].
There are fewer published reports on the treatment of
other benign bone conditions such as giant cell tumour,
enchondroma, eosinophilic granuloma and bone hae-
mangioma. However, we have used RFTA to treat patients
with these diagnoses at our centre, obtaining good pain
control and detecting no growth in follow-up studies.
One study described the treatment of two intracortical
chondromas, preoperatively misdiagnosed as osteoid oste-
omas and treated with RFTA. Radiofrequency appears to
have cured the tumour in one patient, whereas the other
required surgery [26].
There has been a very recent report of technical and
clinical success in treating two patients with solitary
eosinophilic granuloma of bone [27].
The gold standard treatment of giant cell tumour is
extended curettage. Use of an adjuvant therapy such as
phenol, liquid nitrogen or argon beam coagulator may help
to reduce the risk of local recurrence. The created defect
should be carefully ﬁlled with impacted, antibiotic-laden,
morcellized graft bone from the bone bank [28, 29].
Adjuvant therapy plays a major role when the localization
of the tumour makes complete surgical resection chal-
lenging. Cryosurgery was used to treat a sacral giant cell
tumour with a good outcome [30]. We have treated one
patient with an unresectable sacral giant tumour using
partial RFTA and cementation, obtaining pain palliation
and improvement in the quality of life (reduction in pain of
C4 points on a visual analogue scale) during 2 years of
follow-up. Therefore, we consider that RFTA should be
included among adjuvant therapies for giant cell tumours.
There are many therapeutic modalities to treat bone
hemangioma: selective embolization, radiotherapy, cemen-
tation, alcohol ablation and surgery. The selection of
modality depends on the radiological ﬁndings and clinical
status. We have treated a cortical tibial hemangioma with
RFTA, achieving pain control and growth inhibition at
1 year of follow-up. We have found one report in the liter-
ature on the RFTA treatment of multiple lesions of
multifocal epithelioid hemangioendothelioma, an uncom-
mon low-grade malignant vascular neoplasm, with no
evidence of recurrence after a long follow-up [31]. We
therefore believe that RFTA can be added to the armamen-
tarium for treating vascular bone tumours, in isolation or
combinedwith other techniques. RFTA has proven useful to
treat vascular tumours of the liver [32].
Metastases and myeloma
Although bone metastases can be produced by any cancer,
they largely derive from breast, prostate, kidney, lung,
pancreatic, colorectal, stomach, thyroid and ovarian
tumours. The spine is the most frequently involved area,
followed by the pelvis, hip, femurs, ribs and skull [33].
Plasmocytoma and myeloma are haematological malig-
nancies that cause skeletal destruction with osteolytic
lesions and/or pathological fractures. Two-thirds of patients
with myeloma complain of bone pain, which is frequently
located in regions subjected to constraint, e.g., the back,
long bones or pelvis. Although external beam radiation
therapy is the current gold standard treatment for cancer
patients with localizedbone pain, 20–30% of patients do not
experience pain relief with this approach [12]. Radiation
treatment can also result in additional early bone loss due to
inﬂammation, and limited weight bearing should be rec-
ommended during radiation to prevent pathological
fractures. Other treatment options for these patients include
localised (surgery), systemic (chemotherapy, hormonal
therapy, radiopharmaceuticals and bisphosphonates) and
analgesic (opioids and non-steroidal anti-inﬂammatory
Fig. 4 Osteoblastoma of iliac
wing. a CT scan showing 2-cm
lytic lesion. b Electrode in place
during ablation
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are often unsuccessful in providing total pain relief, and
many patients continually require signiﬁcant increases in
the dose of their narcotic medications. The quality of life
and functional capacity of these patients are frequently
compromised.
Considering that the life expectancy of most patients
with bone metastases is limited and that around 12–
20 weeks are usually required before maximum beneﬁt is
obtained from post–radiation therapy [34], the aim must be
to provide the earliest possible pain relief.
RFTA can be used as an alternative to these treatments
[4, 36]. Dupuy et al. were the ﬁrst to report pain relief
using RF ablation of bone metastases [28]. Many sub-
sequent studies have described RF ablation as a useful tool
to relieve disabling pain [4, 12], observing good outcomes
at a few days or weeks after the procedure (Figs. 5–6).
RFTA can also contribute to local control of tumour
growth and can even be used as the deﬁnitive treatment for
small solitary lesions [37].
Monopolar electrodes with a longer active tip can be
used in more extensive bone lesions, although expandable
type electrodes are recommended by some authors when
the osteolysis is large enough to allow the deployment of
multiple tines [4].
Its utilization in combination with other procedures, e.g.,
cementoplasty, is sometimes indicated to reinforce bone
structures and stabilize bones at high risk of pathologic
fracture [38]. The prior use of RFTA theoretically facili-
tates cementation by destroying tissue and forming the
cavity required for the injected cement to ﬁt the necrotic
space, reducing the risk of leakage and avoiding the dis-
placement of tumour tissue usually observed when
cementation is used as single procedure [39]. Bone cement
generates heat up to 80C, which may help to potentiate the
anticancer effects of RFTA [40].
Pain relief is achieved within 4 weeks in 82–97% of
patients treated with vertebroplasty and in 90–100% of
patients treated with RF ablation. Success may be increased
with a combination of the two procedures [40].
Complications
This ablation technique is contraindicated in patients with
cardiac pacemakers, because RF generators can cause
undesirable physiological effects [9].
Possible complications of RF ablation include bleeding,
infection, pathological fractures, injury to adjacent neural
structures, abscess formation and skin and muscle burns.
These burns have been described at the cannula entry
pathway and grounding pads [4, 12].
In weight-bearing joints and lesions near the articular
cartilage, there is a risk of cartilage damage and mechan-
ical weakening of the bone [20].
Fig. 5 Multiple myeloma. a CT
scan shows lytic lesion in
femoral neck. b Electrode in
place. c CT during cementation.
d Radiography after ablation
and cementation
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invade the posterior cortex because of the risk of thermal
damage to nerves. The heating of tissue to 45C in RFTA
is cytotoxic to spinal cord and peripheral nerves [41].
Thermometry may be necessary to avoid nerve injury,
placing a thermocouple near the thecal sac or peripheral
nerves [28].
Conclusions
Several ablation techniques are available to treat bone
tumours. They offer multiple advantages. They are mini-
mally invasive, allow targeted tumour destruction and have
a low rate of complications. To date, the most widely uti-
lized techniques are cryosurgery and RFTA. However,
cryotherapy usually requires open surgery while RFTA can
be performed percutaneously.
RFTA of bone tumours is appropriate when there is a
clear advantage (less invasive, shorter recovery) over sur-
gery or when surgery would not be feasible (e.g., multiple
or unresectable lesions). RFTA is most frequently used for
bone osteoid osteoma and metastases and has become the
gold standard treatment for osteoid osteoma. The outcomes
are excellent and superior to the results of conventional
management.
In metastases, it may be used as a curative therapy in
small, solitary tumours or as palliative treatment in isola-
tion or combined with other modalities such as surgery,
radiotherapy or cementation.
Further indications are now emerging, with reports of
good outcomes in treating other primary bone tumours.
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